OSAAI 2021 Northwest Allergy Forum

October 15, 2021 to October 17, 2021

The Northwest Allergy Forum is a CME educational meeting jointly provided by the American College of Allergy, Asthma & Immunology and the Oregon and Washington Societies of Allergy, Asthma & Immunology. The program is a two-day event with speakers covering a range of topics such as asthma, eczema, food allergy, vocal cord dysfunction and research developments.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 12.75 contact hours.

Commercial Support
This activity is supported in part by independent medical education grant from CSL Behring.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1. Evaluate patients presenting with eosinophilia
  2. Appraise the role of biologics in eosinophilic syndromes
  3.  Integrate biologic therapies into the management of Aspirin Exacerbated Respiratory Disease (AERD)
  4.  Summarize the approach to patients with elevated serum tryptase
  5.  Conduct oral food challenges safely and effectively
  6.  Compare novel food allergy therapeutics
  7.  Synthesize the key components of the diagnosis and management of antibody deficiency syndrome
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

Ambulatory procedure centers

  • Blood banks
  • Diagnostic labs that do not sell proprietary products
  • Electronic health records companies
  • Government or military agencies
  • Group medical practices
  • Health law firms
  • Health profession membership organizations
  • Hospitals or healthcare delivery systems
  • Infusion centers
  • Insurance or managed care companies
  • Nursing homes
  • Pharmacies that do not manufacture proprietary compounds
  • Publishing or education companies
  • Rehabilitation centers
  • Schools of medicine or health science universities
  • Software or game developers

 

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated

Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 CBRN
Course opens: 
10/15/2021
Course expires: 
10/17/2023
Event starts: 
10/15/2021 - 5:00pm
Event ends: 
10/17/2021 - 12:20pm
Rating: 
0

J. Andrew Bird, MD
Speaker: DBV Technologies, Nutricia, Aimmune Therapeutics
Consultant: DBV Technologies, Nutricia, Pfizer, Aimmune Therapeutics, Before Brands
Advisory Board Member: FARE, Prota Therapeutics, AllerGenis
Sponsored Research Funding Recipient: FARE, Aimmune Therapeutics NIH-NIAID, Genentech, Astellas
DSMB member: Pharm Olam International Ltd.
Andrew A. White, MD, FAAAAI, FACAAI
Speaker: Regeneron/Sanofi, AstraZeneca, Optinose
Advisory Board Member: Regeneron/Sanofi, ALK, Optinose, BluePrint Pharmaceuticals, GSK, Genentech

Adam Williams, MD
Speaker: AstraZeneca, Genentech, Sanofi Genzyme/Regeneron

Shyam Joshi, MD
Advisory Board Member: Biocryst, Takeda
Surveys: M3 Global Research    


The following have no relevant financial relationships to disclose:
Paneez Khoury, MD, MHSc
Anil Nanda, MD, FAAAAI, FACAAI
Tyler Yates, MD
Melanie Wayne, FNP
Raj Srinivasan, MD
James Baker, MD
Albert Tsien, MD

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

Ambulatory procedure centers

  • Blood banks
  • Diagnostic labs that do not sell proprietary products
  • Electronic health records companies
  • Government or military agencies
  • Group medical practices
  • Health law firms
  • Health profession membership organizations
  • Hospitals or healthcare delivery systems
  • Infusion centers
  • Insurance or managed care companies
  • Nursing homes
  • Pharmacies that do not manufacture proprietary compounds
  • Publishing or education companies
  • Rehabilitation centers
  • Schools of medicine or health science universities
  • Software or game developers

 

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 CBRN
Please login or create an account to take this course.